Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

Is Goldman’s Oncology Upgrade Altering The Investment Case For BioNTech’s Pipeline-Driven Future (BNTX)?

Goldman Sachs recently upgraded BioNTech SE to Buy, highlighting the company’s position in next-generation immuno-oncology and antibody-drug conjugates, with key oncology data expected in 2026. This endorsement reinforces BioNTech’s shift from its Covid-focused profile toward building a broader oncology franchise powered by its mRNA and antibody platforms. Next, we’ll examine how Goldman Sachs’ confidence in BioNTech’s oncology pipeline could influence the company’s long-term investment...
NYSE:EXP
NYSE:EXPBasic Materials

Eagle Materials Expands Aggregates Footprint While Leaning On Pricing And Buybacks

Eagle Materials (NYSE:EXP) has completed its acquisition of Bullskin Stone and Lime, expanding its aggregates footprint into Western Pennsylvania. The company is advancing sustainability initiatives focused on reducing CO2 intensity and water usage across its operations. Eagle Materials plans broad price increases for 2025 in most cement and wallboard markets. Eagle Materials, a producer of cement, aggregates and gypsum wallboard, is using the Bullskin Stone and Lime acquisition to deepen...
TSE:8309
TSE:8309Banks

Sumitomo Mitsui Trust Group (TSE:8309) Non Performing Loan Improvement Challenges Bearish Risk Views

Sumitomo Mitsui Trust Group (TSE:8309) has just posted its Q3 2026 numbers, with total revenue of ¥403.9 billion and basic EPS of ¥135.88, alongside trailing twelve month EPS of ¥422.33 and net income of ¥298.32 billion. Over recent quarters, revenue has moved between ¥324.4 billion in Q2 2025 and ¥422.9 billion in Q3 2025, while quarterly EPS has ranged from ¥44.50 in Q4 2025 to ¥135.88 in the latest period. This is likely to prompt investors to focus on how these earnings translate into the...
OM:ARJO B
OM:ARJO BMedical Equipment

Arjo (OM:ARJO B) Margin Compression To 3% Challenges Bullish Earnings Growth Narrative

Arjo (OM:ARJO B) has wrapped up FY 2025 with Q4 revenue of SEK 2.8b and Basic EPS of SEK 0.26, capping a year in which trailing 12 month revenue came in at SEK 11.0b and EPS at SEK 1.23. The company has seen quarterly revenue move from SEK 2.99b in Q4 2024 to SEK 2.81b in Q4 2025, while quarterly EPS shifted from SEK 0.64 to SEK 0.26 over the same period. This sets up a picture where investors are likely to focus on how margins are holding up against the headline growth forecasts. See our...
NasdaqGS:HQY
NasdaqGS:HQYHealthcare

How HealthEquity’s GARP Profile and Accelerating Earnings Narrative At HealthEquity (HQY) Has Changed Its Investment Story

Recently published analyst research highlighted HealthEquity as a leading provider of technology-enabled healthcare spending solutions with solid growth characteristics and financial strength, operating in a market supported by structural tailwinds. What stands out is HealthEquity’s identification as a Growth at a Reasonable Price candidate, where accelerating earnings trends intersect with valuation metrics that appear attractive relative to peers. We’ll now examine how HealthEquity’s GARP...